Related Experiment Video
Updated: May 19, 2026
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Imaging Response to Ensartinib in Concurrent Papillary and Anaplastic Thyroid Carcinoma With ALK Rearrangement
Jinbo Gui1,2,3, Fei Fan4, Xiaoli Lan1,2,3
1Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
None:
A 67-year-old woman with coexisting papillary thyroid carcinoma (PTC) and anaplastic thyroid carcinoma (ATC) harbored an ALK rearrangement on FISH. Despite surgery and 2 courses of 131 I treatments, 18 F-FDG PET/CT showed an intensely avid right lower-neck mass extending into the superior mediastinum. The patient was considered radioiodine-refractory (RAIR) and started ensartinib (225 mg once daily). CT at 3 months showed marked regression, with sustained disease control at 12 months. This case illustrates an objective imaging response to ALK-directed therapy in RAIR thyroid carcinoma.
